Pertuzumab

證據等級: L5

預測適應症: 10 個

Pertuzumab: From HER2-Positive Breast Cancer to Progesterone-Receptor Positive Breast Cancer

One-Sentence Summary

Pertuzumab is a HER2-targeted monoclonal antibody already established (per the source clinical trial literature) as an FDA-approved treatment for HER2-positive breast cancer, typically combined with trastuzumab and a taxane. The TxGNN model predicts it may also be effective for progesterone-receptor (PR) positive breast cancer, with 10 clinical trials and 20 publications currently associated — though notably, several of the top trials actually enrolled PR/ER-negative populations, which is the opposite molecular profile of the predicted indication. Given this evidence mismatch plus multiple unresolved data gaps (mechanism of action, safety label, Norway market status), this candidate requires manual curation before further action.

Quick Overview

Item	Content
Original Indication	HER2-positive breast cancer (established use, referenced across the trial evidence base; not separately documented in the Evidence Pack's regulatory fields)
Predicted New Indication	Progesterone-receptor positive breast cancer
TxGNN Prediction Score	99.93%
Evidence Level	L3 (evidence exists but is largely indirect/mismatched — see rationale below)
Norway Market Status	✗ Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data for pertuzumab is not available in this Evidence Pack (flagged as a High-severity data gap). Based on information embedded in the supporting clinical trial records, pertuzumab is a monoclonal antibody that "blocks members of a family of proteins that include Human Epidermal Growth Factor Receptor 2 (HER2)" and is used together with trastuzumab (and typically a taxane such as docetaxel) as standard-of-care therapy for HER2-positive breast cancer, both in the neoadjuvant/adjuvant and metastatic settings.

The predicted new indication — PR-positive breast cancer — is not a distinct disease but a hormone-receptor subclassification that can co-occur with HER2 positivity (i.e., "triple-positive" or HR+/HER2+ breast cancer). Several trials in the evidence set do study this overlap population directly (e.g., NCT02689921 evaluating aromatase inhibitor + pertuzumab/trastuzumab in HR+/HER2+ disease; NCT00999804 comparing lapatinib+trastuzumab ± endocrine therapy in HER2-overexpressing, hormone-receptor-relevant disease), which supports a plausible mechanistic rationale: dual HER2 blockade combined with endocrine therapy in HR+/HER2+ tumors.

However, a substantial portion of the "top" cited trials for this specific prediction (e.g., NCT04629846, NCT03726879) actually enrolled ER/PR-negative or hormone-receptor-unselected HER2-positive populations — the opposite or a non-matching biomarker profile relative to the predicted indication. This suggests the evidence retrieval captured general "pertuzumab + HER2-positive breast cancer" literature rather than PR-positive-specific data, and the prediction itself may simply be re-identifying an already-covered biomarker subgroup of the drug's existing approved use rather than a genuinely novel therapeutic direction.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT04629846	Phase 3	Completed	517	Pertuzumab biosimilar (QL1209) vs. reference pertuzumab + docetaxel in HER2-positive, ER/PR-negative early/locally advanced breast cancer (mismatched biomarker profile)
NCT05802225	Phase 3	Active, not recruiting	398	Biosimilar (BCD-178) vs. Perjeta as neoadjuvant therapy in ER/PR-negative HER2-positive breast cancer
NCT02326974	Phase 2	Active, not recruiting	164	T-DM1 + pertuzumab preoperative therapy; explores HER2 heterogeneity, not PR-status-specific
NCT00545688	Phase 2	Completed	417	Neoadjuvant Herceptin/docetaxel/pertuzumab combinations in HER2-positive breast cancer (unselected for PR status)
NCT06131424	N/A	Completed	1151	Retrospective non-interventional study of HER2-low prevalence and treatment patterns; not PR-specific
NCT03058939	Phase 2	Withdrawn	0	Neoadjuvant paclitaxel in Nigerian women with breast cancer; withdrawn, no enrollment
NCT02689921	Phase 2	Unknown	7	Neoadjuvant aromatase inhibitor + pertuzumab/trastuzumab (chemo-free) specifically in HR+ (ER+/PR+) HER2+ localized breast cancer — directly relevant, but very small (n=7) and unknown status
NCT03726879	Phase 3	Completed	454	IMpassion050: atezolizumab vs. placebo with neoadjuvant chemo + trastuzumab/pertuzumab in early HER2-positive breast cancer; not PR-status stratified
NCT00999804	Phase 2	Active, not recruiting	128	Neoadjuvant lapatinib + trastuzumab ± endocrine therapy in HER2-overexpressing breast cancer; relevant to HR-pathway crosstalk
NCT04675827	Phase 2	Terminated	139	DECRESCENDO: de-escalated adjuvant chemo in HER2+, ER-negative, node-negative early breast cancer — again a mismatched (ER-negative) population

Literature Evidence

PMID	Year	Type	Journal	Key Findings
27179402	2016	RCT (5-yr follow-up)	Lancet Oncology	NeoSphere trial: neoadjuvant pertuzumab + trastuzumab improved pathological complete response in HER2-positive breast cancer
28945833	2017	RCT (Phase 2)	Annals of Oncology	WSG-ADAPT HER2+/HR- trial: 12-week neoadjuvant dual HER2 blockade ± paclitaxel, de-escalation strategy
37166817	2023	RCT	JAMA Oncology	WSG-TP-II: endocrine therapy + trastuzumab/pertuzumab vs. de-escalated chemo in HR-positive/HER2-positive early breast cancer — directly relevant to PR-positive population
38906970	2024	RCT (Phase 3 equivalence)	British Journal of Cancer	QL1209 biosimilar vs. reference pertuzumab in HER2-positive, ER/PR-negative breast cancer (mismatched population)
30106636	2018	RCT (Phase 2, open-label)	J Clin Oncol	PERTAIN trial: trastuzumab + aromatase inhibitor ± pertuzumab in HER2-positive and hormone-receptor-positive metastatic/LABC — directly relevant
35640077	2022	Guideline	J Clin Oncol	ASCO guideline update on systemic therapy for HER2-positive advanced breast cancer
27057657	2016	Review	Cancer Treatment Reviews	Overview of HR/HER2-positive breast cancer biology and crosstalk between ER and HER2 pathways
33662161	2021	Review	Eur J Clin Invest	CDK4/6 and PI3K inhibitors as emerging combination strategies in HER2-positive breast cancer
40983817	2025	Review	Breast Cancer (Tokyo)	Advances in intrinsic signaling pathway interactions and clinical translation of HR+/HER2+ breast cancer
32905036	2020	Review	Cureus	Therapeutic strategies for HER2-positive metastatic breast cancer, covering receptor subtyping including PR status

Norway Market Information

Pertuzumab is not currently marketed in Norway — no authorization records are on file (total_licenses = 0). No original approved-indication text is available from local regulatory sources to verify against the global (FDA/EMA) approved indication referenced in the clinical trial evidence.

Cytotoxicity

Pertuzumab is an antineoplastic biologic (anti-HER2 humanized monoclonal antibody), so this section applies, though it is not a conventional cytotoxic chemotherapy agent.

Item	Content
Cytotoxicity Classification	Targeted therapy (HER2-dimerization inhibitor monoclonal antibody)
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Cardiac function (LVEF) monitoring is standard practice for anti-HER2 therapy given known class-related cardiotoxicity risk, particularly in combination regimens
Handling Protection	Please refer to the package insert warnings and precautions

Safety Considerations

Please refer to the package insert for safety information. (All safety fields — key warnings, contraindications, and drug-drug interactions — are currently unavailable in this Evidence Pack; TFDA/label data acquisition is flagged as a Blocking data gap.)

Conclusion and Next Steps

Decision: Hold

Rationale: A Blocking-severity data gap (missing TFDA label warnings/contraindications) prevents this candidate from entering preliminary safety evaluation (S1), and the mechanism-of-action data needed to assess biological plausibility is also missing. Additionally, the clinical trial evidence most closely associated with this specific prediction shows a notable population mismatch (several key trials enrolled PR/ER-negative, not PR-positive, patients), and the "new" indication may substantially overlap with pertuzumab's already-established use in HER2-positive breast cancer rather than represent a distinct repurposing opportunity.

To proceed, the following is needed:

TFDA package insert / label data (warnings, contraindications) to complete S1 safety evaluation
Confirmed mechanism of action from DrugBank or manufacturer labeling
Manual re-triage of clinical trial and literature relevance flags (majority currently marked "pending") to separate PR-positive-specific evidence from general HER2-positive breast cancer evidence
Clarification of whether this predicted indication represents a genuinely novel use versus a biomarker subgroup already covered by pertuzumab's existing approved indication
Norway/EU regulatory status confirmation, since the drug currently has zero local authorizations on file
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.